Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKRP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation 6.375% Mandatory Convertible Preferred Stock (BRKRP) filings page on Stock Titan is designed to organize and interpret regulatory information related to this preferred equity and its issuer, Bruker Corporation. While no specific SEC filings are listed here in the available data, Bruker’s public communications provide important context for understanding BRKRP as a mandatory convertible preferred security with a stated dividend rate of 6.375%.
In its announcements, Bruker has disclosed a quarterly cash dividend of $3.6745 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. Regulatory filings associated with such securities typically include the original registration statements and prospectus describing the preferred stock terms, including dividend provisions, conversion mechanics, and rights relative to common stock. Periodic reports often discuss capital structure, preferred stock dividends, and any changes affecting holders of BRKRP.
For a company like Bruker, which emphasizes high-performance scientific instruments and analytical and diagnostic solutions, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q can also provide narrative and quantitative detail on its operations in post-genomic life science research, applied and biopharma applications, microscopy and nanoanalysis, industrial and cleantech research, semiconductor metrology, and clinical and molecular diagnostics. These documents help place the BRKRP preferred stock within the broader financial and operational picture of the issuer.
On Stock Titan, AI-powered tools can assist in summarizing lengthy filings, highlighting sections that relate to preferred stock terms, dividend policies, and capital structure, as well as identifying disclosures relevant to Bruker’s scientific and diagnostic activities. This can help readers more quickly locate information that matters for evaluating BRKRP and understanding how regulatory disclosures reflect Bruker’s business and financing choices.
Bruker Corp executive Mark Munch exercised stock options and sold shares in a planned transaction. He exercised options for 2,000 shares of common stock at $22.19 per share and then sold 2,000 shares at $39.90 per share on the same date.
After these transactions, he directly owns 128,443 shares of Bruker common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
BRKR filing reports an intended sale of 2,000 shares of Common Stock on 04/15/2026 via a stock option exercise for cash. The filing also lists prior reported dispositions by Mark R. Munch: 2,000 shares on 03/13/2026 for $70,880 and 2,000 shares on 02/13/2026 for $73,880.
Bruker Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 21, 2026. Investors will elect three Class II directors (Laura A. Francis, John J. Phillips, and Hermann F. Requardt), approve on an advisory basis 2025 executive pay, and ratify PricewaterhouseCoopers as auditor for 2026.
The company highlights a pay-for-performance program combining salary, annual cash incentives and long‑term equity, with no broad perquisites and a clawback policy. In 2025, revenue reached $3.4365 billion but organic revenue and non‑GAAP margins declined, reducing incentive payouts. The proxy also details board structure, committee roles, director compensation and significant share ownership, including CEO Frank Laukien’s 26.6% stake.
BRUKER CORP director Bernard Thierry has filed a Form 3 as a reporting person for the company’s stock. The filing shows no reported transactions, with all buy, sell, acquire, and dispose counts and share amounts listed as zero in the transaction summary.
Bruker Corporation has expanded its Board of Directors to twelve members and appointed Thierry L. Bernard as a Class III director, effective April 1, 2026. He will serve until the 2027 Annual Meeting of Stockholders.
Bernard is currently CEO and Managing Director of QIAGEN N.V., with a previously announced transition plan under which he will step down once a successor is appointed. His background spans senior roles at bioMérieux and other international life-science companies, as well as board leadership at AdvaMedDx and Neogen Corporation. His compensation as a non-employee director will match Bruker’s existing director compensation program, and the company states there are no related-party transactions requiring disclosure. Bruker will later disclose his Board committee assignments.
BRUKER CORP executive Mark Munch reported an option exercise and share sale. On March 13, he exercised stock options for 2,000 shares of common stock at $22.19 per share, then sold 2,000 shares of common stock at $35.44 per share.
Following these transactions, he directly held 128,443 shares of common stock. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, routine liquidity event rather than an opportunistic trade.
Mark R Munch reported sales of Common stock under Rule 144, including multiple transactions dated 01/05/2026, 01/12/2026, 01/15/2026, 02/13/2026, and a stock option exercise on 03/13/2026.
The filing lists individual dispositions of 33,843 shares on 01/05/2026 for $1,680,704, 7,000 shares on 01/12/2026 for $385,000, 2,000 shares on 01/15/2026 for $98,400, and 2,000 shares on 02/13/2026 for $73,880, plus a 2,000-share stock option exercise on 03/13/2026 paid in cash.
Bruker Corp Schedule 13G/A filing reports that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd and Orbis Investment Management (U.S.), L.P. together beneficially own 16,130,961 shares of common stock, representing 10.6% of the class. The filing breaks ownership by reporting person: Orbis Investment Management Ltd holds 15,197,866 shares; Orbis Investment Management (U.S.), L.P. holds 904,773; Allan Gray Australia Pty Ltd holds 28,322. The reporting persons state regulatory equivalence for non‑U.S. filers and disclaim group beneficial ownership.
Bruker Corporation files its annual report describing a global business built around four segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST, focused on advanced scientific instruments and superconducting materials. The company serves life science, biopharma, materials, semiconductor, microbiology, diagnostics, and government markets with NMR, mass spectrometry, X-ray, microscopy, spatial biology, diagnostics, and superconducting technologies.
Bruker reports an aggregate market value of non‑affiliate stock of $4,251,097,535 as of June 30, 2025, with 152,219,250 common shares and 2,760,000 Series A mandatory convertible preferred shares outstanding as of February 20, 2026. Backlog was about $2,569.4 million at December 31, 2025, and the workforce totaled approximately 11,085 employees worldwide. Key risks highlighted include supply chain constraints, tariffs, reduced U.S. and Chinese research funding, geopolitical tensions, currency fluctuations, competition, and potential impairment of goodwill and other long‑lived assets.
Bruker Corporation announced board changes and a new dividend. Director Dr. Cynthia M. Friend will not stand for re-election as a Class II director when her term ends at the 2026 Annual Meeting, and her decision is stated as not due to any disagreement with the company. She will continue to serve until then.
On February 19, 2026, Jack Phillips stepped down as a Class III director and was immediately re-elected as a Class II director, with his board service deemed continuous from January 1, 2026, and his compensation and benefits unchanged. The board also declared a quarterly cash dividend of $0.05 per share on Bruker’s common stock, payable on April 7, 2026 to shareholders of record as of March 23, 2026.